See other companies on Welcome to the Jungle

Rupa Health

Assisting doctors with ordering specialty lab work

Rupa Health logo
21-100 employees
  • Healthcare
  • B2B
  • Biology
  • MedTech
Mission District, San Francisco, CA

Company mission

To modernize this process of ordering specialty labs, so that every doctor can practice root cause medicine.

Led by a woman
Top investors

13% employee growth in 12 months

Our take

Rupa is providing a platform that is making it easier for practitioners to have access to root-cause medicine, from DNA testing to hormone and fertility testing. This is often otherwise inaccessible at average hospitals.

Demand for this holistic approach to medicine has skyrocketed, growing 15-30% annually for the past ten years. But still, there is little access to root-cause medicine. Rupa is building an infrastructure to accommodate the root-cause approach and intends to make it the standard of care for everyone globally.

Backed by world class investors and advisors such as Bessemer Venture partners, Union Square Ventures, and First Round Capital. Rupa has seen exponential month-over-month growth and aims to further strengthen its team and mission as it expands the company and broadens and accelerates product development.

Freddie headshot

Freddie

Company Specialist at Welcome to the Jungle

Benefits

  • Premium medical, dental, and vision benefits
  • Generous paid parental leave
  • Flexible paid time off policy
  • Monthly wellness and productivity stipend
  • Learning & Development stipend

Company values

  • Business Owner
  • Kid at Heart
  • Design Thinker
  • Peak Performance
  • Human

Funding (last 2 of 3 rounds)

Mar 2022

$20m

SERIES A

Aug 2021

$5.8m

SEED

Total funding: $30m

This company has top investors

Leadership

Tara Viswanathan

(CEO & Co-founder)

Founder of VIVE Consulting. Previously worked as a Product Manager at Anova Culinary and in Product & Ops at Parsley Health.

Rosa Hamalainen

(Co-founder)

Previously worked as an Innovation Consultant at Tenovia and was recognised in Forbes 30 under 30 in 2022.